Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Safety and Effectiveness of Advanced Combination Treatments for Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  • By

  • Shellie Radford

  • Daniel Arruda Navarro Albuquerque

  • Zara Najeeb

  • Debangsh Agarwal

  • Anoop John

  • Morris Gordon

  • Vassiliki Sinopoulou

  • Gordon Moran

  • June 11, 2026

Share

  • 1

    This systematic review evaluates the safety of advanced combination therapy (ACT) in adults with inflammatory bowel disease (IBD).

  • 2

    Fifty-two studies involving 2022 participants were included, focusing on various drug combinations for IBD treatment.

  • 3

    Pooled analyses indicated low rates of serious adverse events (SAEs) and treatment discontinuations, but with very low certainty of evidence.

  • 4

    The most common drug combinations were anti-TNFa plus integrin inhibitors and IL-23 plus integrin inhibitors.

  • 5

    The review highlights the need for larger, well-designed trials to better understand the safety and efficacy of ACT in IBD.

Original Source(s)

Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis

  • by Shellie Radford, Daniel Arruda Navarro Albuquerque, Zara Najeeb, Debangsh Agarwal, Anoop John, Morris Gordon, Vassiliki Sinopoulou, Gordon Moran

  • June 11, 2026

Related Content

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease